GlaxoSmithklineGB00BN7SWP63GSKGSK
Financials
Market Cap
$84.85B5Y beta
0.56EPS (TTM)
$1.505Free Float
4.07BP/E ratio (TTM)
13.60Revenue (TTM)
$37.95BEBITDA (TTM)
$11.70BFree Cashflow (TTM)
$2.72BPricing
Analyst Ratings
The price target is $23.75 and the stock is covered by 24 analysts.
Buy
13
Hold
9
Sell
2
Information
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.